Deep learning enhances acute lymphoblastic leukemia diagnosis and classification using bone marrow images.

acute lymphoblastic leukemia bone marrow images classification convolutional neural networks deep learning diagnosis medical image analysis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 31 10 2023
accepted: 27 11 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: epublish

Résumé

Acute lymphoblastic leukemia (ALL) poses a significant health challenge, particularly in pediatric cases, requiring precise and rapid diagnostic approaches. This comprehensive review explores the transformative capacity of deep learning (DL) in enhancing ALL diagnosis and classification, focusing on bone marrow image analysis. Examining ten studies conducted between 2013 and 2023 across various countries, including India, China, KSA, and Mexico, the synthesis underscores the adaptability and proficiency of DL methodologies in detecting leukemia. Innovative DL models, notably Convolutional Neural Networks (CNNs) with Cat-Boosting, XG-Boosting, and Transfer Learning techniques, demonstrate notable approaches. Some models achieve outstanding accuracy, with one CNN reaching 100% in cancer cell classification. The incorporation of novel algorithms like Cat-Swarm Optimization and specialized CNN architectures contributes to superior classification accuracy. Performance metrics highlight these achievements, with models consistently outperforming traditional diagnostic methods. For instance, a CNN with Cat-Boosting attains 100% accuracy, while others hover around 99%, showcasing DL models' robustness in ALL diagnosis. Despite acknowledged challenges, such as the need for larger and more diverse datasets, these findings underscore DL's transformative potential in reshaping leukemia diagnostics. The high numerical accuracies accentuate a promising trajectory toward more efficient and accurate ALL diagnosis in clinical settings, prompting ongoing research to address challenges and refine DL models for optimal clinical integration.

Identifiants

pubmed: 38125946
doi: 10.3389/fonc.2023.1330977
pmc: PMC10731043
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1330977

Informations de copyright

Copyright © 2023 Elsayed, Elhadary, Elshoeibi, Elshoeibi, Badr, Metwally, ElSherif, Salem, Khadadah, Alshurafa, Mudawi and Yassin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Basel Elsayed (B)

College of Medicine, Qatar University, Doha, Qatar.

Mohamed Elhadary (M)

College of Medicine, Qatar University, Doha, Qatar.

Raghad Mohamed Elshoeibi (RM)

Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Amgad Mohamed Elshoeibi (AM)

College of Medicine, Qatar University, Doha, Qatar.

Ahmed Badr (A)

College of Medicine, Qatar University, Doha, Qatar.

Omar Metwally (O)

College of Medicine, Qatar University, Doha, Qatar.

Raghad Alaa ElSherif (RA)

College of Medicine, Qatar University, Doha, Qatar.

Mohamed Elsayed Salem (ME)

Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Fatima Khadadah (F)

Cancer Genetics Lab, Kuwait Cancer Control Centre, Kuwait City, Kuwait.

Awni Alshurafa (A)

Department of Medical Oncology, National Center for Cancer Care and Research, Doha, Qatar.

Deena Mudawi (D)

Department of Medical Oncology, National Center for Cancer Care and Research, Doha, Qatar.

Mohamed Yassin (M)

College of Medicine, Qatar University, Doha, Qatar.
Department of Medical Oncology, National Center for Cancer Care and Research, Doha, Qatar.

Classifications MeSH